MHRA backs LEO Pharma’s Anzupgo in CHE

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Anzupgo (delgocitinib) cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate, from Danish dermatology specialist LEO Pharma.

Last month also saw approval of Anzupgo by the Swiss regulator, adding to previous authorizations in Europe and in Japan, where it is licensed to Japan Tobacco (TYO: 2924).

“The physical symptoms of Chronic Hand Eczema can be debilitating, substantially disrupting patients' lives. Additionally, patients report that the disease can profoundly affect their mental well-being, relationships, and daily activities,” commented Prof Richard Warren, consultant dermatologist at Northern Care Alliance NHS Foundation Trust and The University of Manchester, adding: “Today’s approval of a first, topical JAK inhibitor treatment option for moderate to severe CHE adult patients adds to the treatment options available for healthcare professionals and patients.”